Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Diazoxide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 4,961Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    US FDA approves first treatment for Prader-Willi syndrome
    US FDA approves first treatment for Prader-Willi syndrome

    27 Mar 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-greenlights-first-ever-treatment-rare-metabolic-disorder-2025-03-26/

    REUTERS
    27 Mar 2025
    Share Share
    Soleno Therapeutics Announces FDA Review Extension for DCCR Tablets
    Soleno Therapeutics Announces FDA Review Extension for DCCR Tablets

    26 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/26/2987503/0/en/Soleno-Therapeutics-Announces-FDA-Extension-of-Review-Period-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-in-Prader-Willi-Syndrome.html

    GLOBENEWSWIRE
    26 Nov 2024
    Share Share
    Soleno Presents Diazoxide Choline in Prader-Willi Syndrome
    Soleno Presents Diazoxide Choline in Prader-Willi Syndrome

    14 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/14/2981587/0/en/Soleno-Therapeutics-Announces-Oral-Presentations-featuring-Diazoxide-Choline-Extended-Release-DCCR-Tablets-in-Prader-Willi-Syndrome-at-ESPE-2024.html

    GLOBENEWSWIRE
    14 Nov 2024
    Share Share
    Soleno Therapeutics Announces DCCR Regulatory Update
    Soleno Therapeutics Announces DCCR Regulatory Update

    08 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/en/news-release/2024/10/08/2959708/0/en/Soleno-Therapeutics-Announces-Regulatory-Update-on-DCCR-diazoxide-choline-Extended-Release-Tablets-to-Treat-Prader-Willi-Syndrome.html

    GLOBENEWSWIRE
    08 Oct 2024
    Share Share
    Soleno Therapeutics To Present At Cantor Healthcare Conference
    Soleno Therapeutics To Present At Cantor Healthcare Conference

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2947017/0/en/Soleno-Therapeutics-to-Present-at-2024-Cantor-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share
    Soleno Therapeutics Announces Inducement Grants Under Nasdaq Rule
    Soleno Therapeutics Announces Inducement Grants Under Nasdaq Rule

    19 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/19/2932445/0/en/Soleno-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    19 Aug 2024
    Share Share